Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc (GENFF) is a UK-headquartered biotechnology company with R&D facilities in Belgium, focused on longevity research and SIRT6-based gene therapies. This news page aggregates regulatory announcements and corporate updates related to Genflow’s scientific programs, intellectual property, and capital markets activity.
Readers can follow developments in Genflow’s gene therapy pipeline, including its 12‑month proof‑of‑concept clinical trial in aged dogs that evaluates a SIRT6‑centenarian gene therapy for age‑related decline. Company updates have highlighted dosing milestones, safety and tolerability observations in elderly dogs, and the design of blinded clinical assessments using biomarkers linked to sarcopenia, healthspan, and lifespan.
The news flow also covers Genflow’s plans to explore GF‑1002 in MASH (Metabolic Dysfunction‑Associated Steatohepatitis), reflecting its interest in metabolic and age‑related disorders. In addition, announcements detail progress in the company’s intellectual property strategy, such as European Patent Office publications recognizing the patentability of SIRT6 variant claims and the publication of a second European patent application titled “SIRT6 Variant for NASH.”
Investors and observers will also find information on equity issues, warrants, and voting rights, including share subscriptions, warrant terms, and total issued share capital figures disclosed for regulatory purposes. Notifications of major holdings and participation in sector events, such as the J.P. Morgan Healthcare Conference, appear in the same stream.
By reviewing the GENFF news page, users can see how Genflow communicates the evolution of its SIRT6 gene therapy platform, its animal health and human-focused programs, and its ongoing regulatory and capital markets disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.